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Introduction 
Subarachnoid hemorrhage (SAH) is a type of stroke that occurs after the rupture of a 
brain artery into the subarachnoid meningeal space.  Symptoms of the stroke include hemiplegia, 
slurred speech, loss of motor skills, and one-sided weakness.1 Subarachnoid hemorrhagic strokes 
are more fatal than other more common strokes.2 In many cases, patients are also at risk of 
complications such as septicemia, headache, stroke, and hydrocephalus.3 Additionally, SAH 
patients can have continued vasoconstriction, arterial narrowing, and meningitis complicating 
their recovery.4  
The release of blood into the subarachnoid 
space provides an opportunity for the introduction of 
iron-containing compounds to the cerebrospinal fluid (CSF). Highly-reactive free iron can 
participate in Fenton reactions, generating free radicals and ultimately reactive oxygen species 
(ROS) that may result in tissue damage (Figure 1).5 The relative contribution of ROS production 
to brain injury in SAH and whether there is a compensatory up regulation of small molecule 
antioxidants within the CSF has been incompletely explored.   
Mass-spectroscopy based (MS-based) metabolomics has been used in the past to analyze 
and compare small endogenous molecules.6 Liquid chromatography mass spectrometry (LC-
MS/MS) can separate, detect, and characterize biochemicals (less than 1000Da) based on their 
mass-to-charge ratios and retention time.6–8 Hydrophilic interaction liquid chromatography mass 
spectrometry (HILC-MS) is one of the primary methods used to detect polar metabolites which 
includes amino acids, citric acid cycle intermediates, and other biologically important small 
molecules.9 A typical workflow for the acquisition of metabolomics datasets include compound 
Figure 1: Fenton chemistry: radical initiation.  
Fe2+ + H2O2  Fe3+ + OH- + OH 
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detection by LC-MS/MS followed by bioinformatics analysis in order to determine statistically 
significant changes between experimental samples. In this study, we use Elements software 
(version 1.2.1, Proteome Software, Inc.) to preform automated identifications and statistical 
comparisons between metabolites detected in CSF isolated from SAH patients and normal 
controls.10   
Disturbances of iron metabolism caused by bleeding may directly impact neuronal 
function. As in Alzheimer patients, much of the neurodegeneration is due to oxidative stress in 
the brain caused by the break down of hemin.11 The same oxidative stress is present with the 
degradation of hematin in CSF. When hematin is degraded in the cytosol of the cell, it causes the 
release of Fe2+which is then oxidized into Fe3+. The oxidation of the iron produces the radical 
hydroxyl groups, which damages proteins and DNA (Figure 1).11 The disruption of these 
molecules result in subsequent apoptosis in neuronal cells.12 
In this study, we also explored iron toxicity on neuroblastoma cells by using an MTT 
assay. The treatment of this cell line with retinoic acid 
induces differentiation of the cells into a primary neuronal 
phenotype characterized by process extension and the 
production of neurotransmitters.13,14  In addition, we utilized 
global metabolomics to identify changes in the CSF due to 
SAH. We found that treatment of differentiated 
neuroblastomas with hematin, an oxidation product of 
hemoglobin, resulted in cell death in concentrations higher 
than 15.62 μM. Hemin and hematin are porphyrin molecules with very similar structures. In 
hemin, the axial ion is chloride. While, in hematin the coordinating ion is an hydroxide ion 
Figure 2: The structure of hematin. 
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(Figure 2).15 Both iron donors contain a ferric iron at the center. The chloride ion has as higher 
affinity for binding oxygen than the hydroxide ion, and hemin is a primary component in the 
formation of hemoglobin.16 The higher affinity for binding oxygen primes hemin for oxygen 
transport in blood. Hematin has a hydroxide ion that makes it a primary molecule in heme 
signaling.17 Previous studies have shown that the iron coordinated in hemin altered the 
concentration of iron within cells. Owen et al. found that there is Fenton-chemistry occurring in 
the cells following the incubation of astrocytes with iron-containing hemin. They were able to 
measure the concentrations of Fe2+ and Fe3+, and found that they were both present in abundance 
in the cytoplasm of the cell following iron treatment. The ferric ions were found in greater 
concentration with a hemin containing iron treatment than a non-hemin containing iron 
treatment.  Previous studies found that the cells had a better ability to store iron in ferritin when 
it was introduced through a non-hemin containing iron source. 11 These studies provide a 
foundation to further examine metal-mediated pathology in SAH.   
Methods and Materials 
Cell Culture  
The SH-SY5Y human neuroblastoma cell line (ATCC CLR-2266) was cultured in a 1:1 
mixture of ATCC-formulated Dulbecco’s Modified Eagle Medium (DMEM) and F12 medium 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin streptomycin. The cells 
were incubated at 37ºC and 5% CO2. This is in accordance with ATCC guidelines for cell 
maintenance. After cells had reached 100% confluency, they were split. Media and trypsin-
EDTA were warmed to 37ºC in a hot water bath. The media was removed from the T75 plates 
and placed in a 50mL falcon tube. 2mL of trypsin-EDTA was added to the T75 flasks. The cells 
were treated with trypsin-EDTA for 2 minutes followed by the addition of 3mL of tissue culture 
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medium. All 5 ml of solution was subsequently added to the 50mL Falcon tube. The cell solution 
was then centrifuged at 1000 RPM and 4ºC for 10 minutes. After the centrifuge was completed, 
all of the solution was removed carefully as to not disturb the pellet. The pellet was then 
suspended in at least 2mL of media. The cell solution was then either plated in a T75 for 
continued growth, or used for a 96-well plate. 
Iron Treatment and Measurement of Cell Viability  
 Prior to treatment with iron containing compounds, cells were plated at a density of 2.6 
x106 cells/well in a final volume of 100 μl and allowed to adhere for twenty-four hours. Porcine 
hematin (Sigma- Aldrich, St Louis, MO) was dissolved in DMSO to create a final concentration 
of 2 mM. This stock solution was then serially diluted to 1μM concentration solution. Cells were 
incubated for an additional twenty-four hours. Following the incubation, Resazurin was added to 
each well at 10% of the final well volume. The resazurin was left to incubate for at least two 
hours and then the plate was read using the SpectraMax M2 plate reader.  The absorbance was 
measured at a reference wavelength 690nm. The absorbance at 690nm was subtracted from the 
absorbance at 600nm.  Fluorescent emission was measured at 590nm.  
 For differentiating the neuroblastomas, the cells were plated in the same way as 
previously described. However, 1μL of retinoic acid was added to each well and allowed to 
incubate for twenty-four hours prior to the administration of hematin.  
Metabolite Extraction of Cerebrospinal fluid 
The institutional review board at the Cleveland Clinic approved the collection and use of 
human CSF samples. CSF samples were stored in liquid nitrogen prior to extraction. The 
samples were thawed at 4°C and 100μL of the CSF was collected in Eppendorf tubes. 400μL of 
4X methanol was added to each of the samples to denature the CSF. Samples were then 
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incubated at -20°C for two hours and centrifuged at 18,000 x g at 4°C for twenty minutes. This 
process separates the denatured proteins from extracted metabolites. The supernatants were 
collected and dried in a CentriVap Concentrator (LACONCO, Kansas, MO, US) at room 
temperature. The dried samples were reconstituted for analysis in 200μL of 35% acetonitrile in 
water.18 Samples were then analyzed using LC-MS. 
HILIC-MS 
Resuspended samples were analyzed on a Micro200 LC (Ekisgent, Redwood, CA, USA) 
coupled with a HILC column (Luna 3μ NH2 100Å, 150mmx 1.0mm, Phenomenex Torrance, CA, 
USA). HILIC employs two different mobile phases of water and acetonitrile respectively. Each 
phase contained an addition of 5mM ammonium acetate and 5mM ammonium hydroxide (pH 
8.4). Samples were subsequently analyzed with the following gradient: 0 min 98%, 0.5 min 98%, 
1 min 95%, 5 min 80%, 6 min 46%, 13 min 14.7%, 17 min 0%, 17.1 min 100%, 23 min 100%.  
Following separation, samples were introduced into a 5600+ Triple ToF Mass 
Spectrometer (SCIEX, Framingham, MA, USA). Analysis was done in both in positive and 
negative mode. Nitrogen (N2) was used as the ion source nebulizer gas (GS1) at 15 psi, the 
heater gas (GS2) was set to 20 psi, and the curtain gas (CUR) was set to 25 psi. The 
accumulation time was set to 250ms for the precursor ion acquisition. The positive mode used a 
+5000 V ion spray voltage and a +100 V declustering potential (DP). Fragmentation data was 
collected using a collision energy spread (CES) of +(20-80) V under positive mode. For negative 
mode, data was collected using CES of -(20-80) V.  
Elements for Metabolic software (version 1.2.1, Proteome Software, Inc.) was used for 
data analysis following HILC-MS.19 This software identifies compounds from MS spectra using 
a public database. In this case, the NIST library and combined HMDB and NIST endogenous 
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Figure 5: Undifferentiated SH-SY5Y 
treated with concentrations of hematin. 
Error bars represent standard deviation.  
Figure 4: Differentiated SH-SY5Y 
treated with concentrations of hematin. 
Error bars represent standard deviation.    
library were used for metabolite selection.20 Pathways were subsequently mapped using 
Cytoscape software.21 
   
Results  
The goal of these experiments was to determine metabolic alterations associated with 
SAH. This was achieved by using in vitro viability testing and LC-MS analysis. It had been 
previously proposed that one source of oxidative damage in the brain is the iron-mediated 
production of highly reactive radical iron molecules.22 The first task was to identify the 
concentration iron-containing hematin becomes toxic for the neural cells. The neuroblastomas 
were treated with varying concentrations of porcine hematin. The difficulty came with 
determining the concentration of DMSO that the hematin was soluble in, but didn’t result in 
unnecessary cell death. Figures 4 and Figures 5 show undifferentiated and differentiated 
neuroblastoma cells treated with hematin concentrations dissolved in 30% DMSO in media. In 
total, DMSO accounted for 3% of the well volume. There was not a clear dose-response 
relationship with respect to hematin-induced cell death. Very low concentrations or high 
concentr
ations of 
hematin 
appeared 
to impair 
the 
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viability of the cells. However, at 62.5µM and above, there was a consistent loss of viability. 
Additionally, the vehicle had some impact on the viability of the cells. As shown in both Figure 
4 and Figure 5, there was a loss of viability in cells treated only with 30% DMSO in Media. We 
discovered, during the differentiation protocol, that the cells needed to proliferate for a full 
twenty-four hours prior to being treated with the retinoic acid. This gives the neuroblastoma cells 
an opportunity to adhere to the plate. The standard error bars are large in the differentiated cells, 
because the cells were not given this time. However, in both the differentiated and 
undifferentiated cells, there was a significant loss in viability at 62.5µM and above.  
We next analyzed CSF samples that were collected from healthy patients and patients 
who suffered SAH. The two sample groups were analyzed by LC-MS in order to determine 
metabolic changes between the two groups. Metabolite and metabolic pathway changes were 
explored by using Elements and Cytoscape. In Elements, metabolites that showed a fold change 
less than -3 and greater than 3, and that had a p-value less than or equal to 0.25 were selected as 
statistically significant due to the small n and the high variability in human samples.  
Volcano plots showing statistically significant changes between the patients and controls 
are shown in Figures 6 and 7. The volcano plots compare the p-value s to the log fold intensities 
in order to determine which metabolites are significantly changed between sample groups. 
Positive fold changes signify an up regulation; while, negative fold changes signify a down 
regulation of the metabolite. Metabolites that were increased or decreased compared to controls 
were researched to determine their origin. Those that are endogenous were examined by using 
Cytoscape to map the potential pathway and enzyme interactions. For each metabolite the 
corresponding KEGG ID was found and used to create a network pathway in Cytoscape.  
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Figure 6: Volcano plot of 
the positive mode 
comparing control 
patients to SAH patients, 
made in Elements.  
Figure 7:  Volcano plot 
of the negative mode 
comparing control 
patients to SAH 
patients, made in 
elements.  
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Figure 8: Pathways demonstrating significant metabolite change based on LC-MS data. 
Presqualene diphosphate and 20-Hydroxyl-Leukotriene E4 are both highlighted green 
showing significance.  
 
 Significant changes were primarily observed when metabolites were analyzed in positive 
mode. In patients who have suffered an SAH, there was a down regulation of 20-hydroxy-
Leukotriene E4.  Leukotrienes are lipid metabolites derived from arachidonic acid, an ω-6 fatty 
acid, and plays a role in membrane system.23 Arachidonic acid is a major component of the cell 
membranes and has been detected in synaptosomes, mitochondria, and microsomes.23 When free 
radicals are introduced to the cell it can trigger the peroxidation of arachidonic acid and 
subsequent production of pro-inflammatory lipid mediators.24 In patients who suffered a SAH, 
we also saw an upregulation of adrenic acid. Many of the phospholipids in the neuronal cell 
membranes are comprised of arachidonic and adrenic acid. Adrenic acid is considered to be a 
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prothrombotic factor in the brain.25,26 In addition, adrenic acid has been linked to neuro 
degeneration. A recent study demonstrated an upregulation of adrenic acid in the grey matter of 
Alzheimer patients when compared to control patients.27 We also observed an upregulation of γ-
glutamyl-L-putrescine. This metabolite is part of the putrescine degradation pathway and 
putrescine can contribute to the production of the inhibitory neurotransmitter, GABA.28 
Therefore, alterations in putrescine levels after SAH may impact the balance between inhibitory 
transmitters such as GABA and excitatory neurotransmitters such as glutamate. Finally, the 
stroke patients showed an upregulation of testosterone signaling.  Testosterone is reduced to 5α-
dihydrotestosterone (DHT) and estrogens by the enzyme 5α-reductase. The enzyme itself is very 
highly concentrated in the myelin membranes.29 
Discussion 
In this study, we showed that hematin concentrations higher than 15.62 μM induced cell 
death in neuronal cell line. In addition, we were able to preliminarily identify metabolic 
pathways associated with SAH in CSF samples. Our focus was primarily on testosterone 
metabolism, amino acid metabolism, and leukotriene synthesis. In the future, we would like to 
confirm the results from our small sample size to a larger set of patients and quantify metabolite 
levels with selective reaction monitoring. Additionally, we need to modify the cell culture 
conditions to establish the concentration of DMSO that can solubilize the hematin while 
effectively measuring cell death. This would allow us to link alterations in CSF with changes in 
neuronal function induced by iron overload.  
 Our focus was to determine how the reactive oxygen species produced during SAH were 
impacting the levels of small molecule metabolites. The LC-MS data is limited due to the time 
restraints of the project and the number of CSF samples. However, some promising data arose 
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out of this experiment. One of the pathways found to be perturbed by SAH was leukotriene 
synthesis. Arachidonic acid, the precursor of leukotriene synthesis is often used as an 
inflammatory marker in mice.30 20-Hydroxy-Leukotriene E4 is a lipid oxidation product of 
leukotriene E4 and is produced in traumatic brain injury. This may contribute to edema after 
trauma.31 Adrenic acid has a very similar structure to arachidonic acid and is also a ω -6 fatty 
acid and also showed an increase in CSF after SAH.32 Adrenic acid can induce arterial 
constriction33 and can induce inflammation in other diseases such as non-alcoholic fatty liver 
disease.34 Therefore, the upregulation of this lipid may play a role in promoting post-stroke 
inflammation as well as vasocontstriction associated with further injury.  
Testosterone metabolism in the brain is integral to the composition of grey matter.35 
Multiple cell types, such as neurons, astrocytes and oligodendrocytes, express the capability of 
reducing testosterone into various metabolites.29 Estrogens and DHT that are reduced in the brain 
participate in remyelinating following neurodegenerative disease such as multiple sclerosis 
(MS). DHT has a higher binding affinity than testosterone for brain androgen receptors and has 
been shown to work as a remyelinating factor in the absence of testosterone.36 DHT was 
discovered to combat the inflammation and demyelination of the spinal cord as MS progresses.36 
It is possible that testosterone signaling reduction in the brain is contributing to the increased 
inflammation following the SAH.  
γ-Glutamyl-L-putrescine upregulation indicates preturbations in polyamine metabolism, 
which is linked to both methylation reactions and NO synthesis.37 It is synthesized from the ATP 
driven reaction between putrescine and L-glutamate.38 Polyamines can directly influence brain 
function by altering the activity of ion channels, and antagonists have been shown to have 
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neuroprotective effects during ischemic stroke.39 The functional outcomes of dysregulation 
remain to be explored during SAH.  
Conclusion 
 A subarachnoid hemorrhage causes irreversible damage to the brain tissue. The 
mechanism by which the tissue is injured is not well characterized. SH-SY5Y cells were used to 
mimic neuronal cells and determine iron toxicity.  We found that high concentrations of hematin 
can be toxic for neuronal cell lines. However, more research is needed to determine the precise 
concentration that affects cell viability. LC-MS data was obtained from SAH patients and control 
patients. Even with the small patient number we observe alterations in metabolism associated 
with SAH. The affected pathways were mapped using the Cytoscape program. This showed a 
change in polyamine metabolism, leukotriene level, and testosterone metabolism. The significant 
change in the presence of these metabolites could contribute to increased inflammation and 
tissue damage in the brain after SAH.  
 
 
i
g
u
r
e
 
9
:
 
S
m
a
l
l
 
m
o
l
e
c
u
l
e
s
 
i
d
e
n
t
i
f
i
e
d
 
u
s
i
n
g
 
L
C
-
M
S
.
 
T
h
e
 
m
e
t
a
b
o
l
i
t
e
s
 
w
e
r
 
14 
 
Reference 
(1)  Nishikawa, T.; Okamura, T.; Nakayama, H.; Miyamatsu, N.; Morimoto, A.; Toyoda, K.; 
 Suzuki, K.; Toyota, A.; Hata, T.; Yamaguchi, T. J.Effects of a Public Education 
 Campaign on the Association Between Knowledge of Early Stroke Symptoms and 
 Intention to Call an Ambulance at Stroke Onset: The Acquisition of Stroke Knowledge 
 (ASK) Study. Epidemiol. 2016, 26 (3), 115–122. 
(2)  D’Souza, S. J. Aneurysmal Subarachnoid Hemorrhage. Neurosurg. Anesthesiol. 2015, 27 
(3), 222–240. 
(3)  Rumalla, K.; Smith, K. A.; Arnold, P. M.; Mittal, M. K. Subarachnoid Hemorrhage and 
Readmissions: National Rates, Causes, Risk Factors, and Outcomes in 16,001 
Hospitalized Patients. World Neurosurgery 2017. DOI: 10.1016 
(4)  Lucke-Wold, B.; Logsdon, A.; Manoranjan, B.; Turner, R.; McConnell, E.; Vates, G.; 
Huber, J.; Rosen, C.; Simard, J. Int. J. Mol. Sci. 2016, 17 (4), 497. 
(5)  Provencio, J. J. Inflammation in subarachnoid hemorrhage and delayed deterioration 
associated with vasospasm: a review. Acta Neurochir. Suppl. 2013, 115, 233–238. 
(6)  Patti, G. J.; Tautenhahn, R.; Rinehart, D.; Cho, K.; Shriver, L. P.; Manchester, M.; 
Nikolskiy, I.; Johnson, C. H.; Mahieu, N. G.; Siuzdak, G. Anal. Chem. 2013, 85 (2), 798–
804. 
(7)  Idle, J. R.; Gonzalez, F. J. Metabolomics. Cell Metab. 2007, 6 (5), 348–351. 
(8)  Tolstikov, V. Metabolomics: Bridging the Gap between Pharmaceutical Development and 
Population Health. Metabolites 2016, 6 (3), 20. 
15 
(9)  Cubbon, S.; Antonio, C.; Wilson, J.; Thomas-Oates, J. Metabolomic applications of 
HILIC-LC-MS. Mass Spectrom. Rev. 2010, 29 (5), 671–684. 
(10)  Ostertagová, E.; Ostertag, O. Methodology and Application of Oneway ANOVA Am. J. 
Mech. Eng. 2013, 1 (7), 256–261. 
(11)  Owen, J. E.; Bishop, G. M.; Robinson, S. R. Uptake and Toxicity of Hemin and Iron in 
Cultured Mouse Astrocytes. Neurochem. Res. 2016, 41 (1–2), 298–306. 
(12)  Uttara, B.; Singh, A.; Zamboni, P.; Mahajan, R. Oxidative Stress and Neurodegenerative 
Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic 
Options. Current Neuropharmacology 2009, 7 (1), 65–74. 
(13)  Shipley, M. M.; Mangold, C. A.; Szpara, M. L. Differentiation of the SH-SY5Y Human 
Neuroblastoma Cell Line. Journal of Visualized Experiments 2016, No. 108. DOI 
10.379/53193 
(14)  Agholme, L.; Lindström, T.; Kågedal, K.; Marcusson, J.; Hallbeck, M. J. An In Vitro 
Model for Neuroscience: Differentiation of SH-SY5Y Cells into Cells with Morphological 
and Biochemical Characteristics of Mature Neurons. Alzheimer’s Dis. 2010, 20 (4), 1069–
1082. 
(15)  Gildenhuys, J.; Roex, T. le; Egan, T. J.; de Villiers, K. A. J.The Single Crystal X-ray 
Structure of β-Hematin DMSO Solvate Grown in the Presence of Chloroquine, a β-
Hematin Growth-Rate Inhibitor. Am. Chem. Soc. 2013, 135 (3), 1037–1047. 
(16)  Eike, J. H.; Palmer, A. F. Effect of Cl- and H+ on the oxygen binding properties of 
glutaraldehyde-polymerized bovine hemoglobin-based blood substitutes. Biotechnol. 
Prog. 20 (5), 1543–1549. 
(17)  Liu, Q.; Wong-Riley, M. Postnatal development of N-Methyl-d-Aspartate receptor 
16 
subunits 2A, 2B, 2C, 2D, and 3B immunoreactivity in brain stem respiratory nuclei of the 
rat. Neuroscience 2010, 171 (3), 637–654. 
(18)  Soga, T. Development and Application of Capillary Electrophoresis-Mass Spectrometry 
Methods to Metabolomics. Metabolomics 2005, 7–24.  
(19)  Elements for Metabolomic   
http://www.proteomesoftware.com/products/elements/metabolomics/ (accessed Dec 10, 
2017). 
(20)  Wishart, D. S.; Knox, C.; Guo, A. C.; Eisner, R.; Young, N.; Gautam, B.; Hau, D. D.; 
Psychogios, N.; Dong, E.; Bouatra, S.; Mandal, R.; Sinelnikov, I.; Xia, J.; Jia, L.; Cruz, J. 
A.; Lim, E.; Sobsey, C. A.; Shrivastava, S.; Huang, P.; Liu, P.; Fang, L.; Peng, J.; 
Fradette, R.; Cheng, D.; Tzur, D.; Clements, M.; Lewis, A.; De Souza, A.; Zuniga, A.; 
Dawe, M.; Xiong, Y.; Clive, D.; Greiner, R.; Nazyrova, A.; Shaykhutdinov, R.; Li, L.; 
Vogel, H. J.; Forsythe, I. B Vitamins and the Brain: Mechanisms, Dose and Efficacy--A 
Review. 
Nucleic Acids Res. 2009, 37 (Database issue), D603-10. 
(21)  Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N. S.; Wang, J. T.; Ramage, D.; Amin, N.; 
Schwikowski, B.; Ideker, T. Cytoscape: a software environment for integrated models of 
biomolecular interaction networks. 
Genome Res. 2003, 13 (11), 2498–2504. 
(22)  Pieniazek, A.; Gwozdzinski, K. Changes in the conformational state of hemoglobin in 
hemodialysed patients with chronic renal failure. Oxid. Med. Cell. Longev. 2015, 2015, 
783073. 
(23)  Murphy, R. C.; Gijón, M. A. Biochem. J. 2007, 405 (3), 379–395. 
17 
(24)  Anthonymuthu, T. S.; Kenny, E. M.; Bayır, H. Therapies targeting lipid peroxidation in 
traumatic brain injury.Brain Res. 2016, 1640 (Pt A), 57–76. 
(25)  Human Metabolome Database: Showing metabocard for Adrenic acid (HMDB0002226) 
http://www.hmdb.ca/metabolites/HMDB0002226 (accessed Jan 22, 2018). 
(26)  Tardy, B.; Bordet, J. C.; Berruyer, M.; Ffrench, P.; Dechavanne, M. Priming effect of 
adrenic acid (22:4(n-6)) on tissue factor activity expressed by thrombin-stimulated 
endothelial cells.  Atherosclerosis 1992, 95 (1), 51–58. 
(27)  Bailey, E. &; Lockwood, E. A.; Bailey, E.; &taylor. Lipids and Development of the 
Human Brain J. Biochem 1976, 15 (6). 
(28)  Caron, P. C.; Kremzner, L. T.; Cote, L. J.  GABA and its relationship to putrescine 
metabolism in the rat brain and pancreas. Neurochem. Int. 1987, 10 (2), 219–229. 
(29)  Celotti, F.; Melcangi, R. C.; Negri-Cesi, P.; Poletti, A. J. Testosterone metabolism in brain 
cells and membranes Steroid Biochem. Mol. Biol. 1991, 40 (4–6), 673–678. 
(30)  Lee, H.; Villacreses, N. E.; Rapoport, S. I.; Rosenberger, T. A. J. In vivo imaging detects 
a transient increase in brain arachidonic acid metabolism: a potential marker of 
neuroinflammation Neurochem. 2004, 91 (4), 936–945. 
(31)  Schuhmann, M. U.; Mokhtarzadeh, M.; Stichtenoth, D. O.; Skardelly, M.; Klinge, P. M.; 
Gutzki, F. M.; Samii, M.; Brinker, T. Temporal profiles of cerebrospinal fluid 
leukotrienes, brain edema and inflammatory response following experimental brain injury 
Neurol. Res. 2003, 25 (5), 481–491. 
(32)  Kopf, P. G.; Zhang, D. X.; Gauthier, K. M.; Nithipatikom, K.; Yi, X.-Y.; Falck, J. R.; 
Campbell, W. B. Adrenic acid metabolites as endogenous endothelium-derived and zona 
18 
glomerulosa-derived hyperpolarizing factors.Hypertens. (Dallas, Tex.  1979) 2010, 55 (2), 
547–554. 
(33)  Mössner, J.; Hammermann, R.; Racké, K. Concomitant Down-Regulation of L-Arginine 
Transport and Nitric Oxide (NO) Synthesis in Rat Alveolar Macrophages by the 
Polyamine Spermine. Pulmonary Pharmacology & Therapeutics 2001, 14 (4), 297–305. 
(34)  Horas H Nababan, S.; Nishiumi, S.; Kawano, Y.; Kobayashi, T.; Yoshida, M.; Azuma, T. 
Adrenic acid as an inflammation enhancer in non-alcoholic fatty liver disease Arch. 
Biochem. Biophys. 2017, 623–624, 64–75. 
(35)  Skinner, E. R.; Watt, C.; Besson, J. A. O.; Best, P. V. Brain 1993, 116 (3), 717–725. 
(36)  Hussain, R.; Ghoumari, A. M.; Bielecki, B.; Steibel, J.; Boehm, N.; Liere, P.; Macklin, W. 
B.; Kumar, N.; Habert, R.; Mhaouty-Kodja, S.; Tronche, F.; Sitruk-Ware, R.; 
Schumacher, M.; Ghandour, M. S. Brain 2013, 136 (1), 132–146. 
(37)  Mössner, J.; Hammermann, R.; Racké, K. Pulm. Pharmacol. Ther. 2001, 14 (4), 297–305. 
(38)  Human Metabolome Database: Showing metabocard for Gamma-glutamyl-L-putrescine 
(HMDB0012230) http://www.hmdb.ca/metabolites/HMDB0012230 (accessed Jan 20, 
2018). 
(39)  Li, J.; Doyle, K. M.; Tatlisumak, T. Curr. Med. Chem. 2007, 14 (17), 1807–1813. 
 
19 
 
Acknowledgments 
 Great thanks are due to Dr. Shriver for giving me the opportunity to work in her lab and 
learn from her all that I can. I would also like to thank the other graduate students of the lab who 
helped me and encouraged me to continue my work with the group. I hope to apply all I have 
learned from this group of amazing people.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
20 
Safety Considerations 
 A sterile technique was utilized during cell cultures and handling of biohazardous 
materials. This included wearing protective eyewear, gloves, and a sterile hood any time 
biohazardous materials were handled. Maintaining a sterile work place also included using 
autoclaved items and spraying all items and hood with 70% ethanol prior to experimentation. 
Proper lab attire was worn including lab coat, long pants, close-toed shoes, protective eyewear, 
and gloves. Chemicals were disposed of in the appropriate waste containers. If there was a need 
for chemical disposal or a lab emergency, then UA Environmental Health and Safety was 
contacted and able to assist.  
 
 
